T-cell Surface Glycoprotein CD4 - Pipeline Insight, 2022
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “T-cell Surface Glycoprotein CD4- Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in T-cell Surface Glycoprotein CD4 pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
T-cell Surface Glycoprotein CD4: Overview
In molecular biology, CD4 (cluster of differentiation 4) is a glycoprotein found on the surface of immune cells such as T helper cells, monocytes, macrophages, and dendritic cells. It was discovered in the late 1970s and was originally known as leu-3 and T4 (after the OKT4 monoclonal antibody that reacted with it) before being named CD4 in 1984. In humans, the CD4 protein is encoded by the CD4 gene. CD4+ T helper cells are white blood cells that are an essential part of the human immune system. They are often referred to as CD4 cells, T-helper cells or T4 cells. They are called helper cells because one of their main roles is to send signals to other types of immune cells, including CD8 killer cells, which then destroy the infectious particle. If CD4 cells become depleted, for example in untreated HIV infection, or following immune suppression prior to a transplant, the body is left vulnerable to a wide range of infections that it would otherwise have been able to fight.
Structure of T-cell Surface Glycoprotein CD4
Like many cell surface receptors/markers, CD4 is a member of the immunoglobulin superfamily. It has four immunoglobulin domains (D1 to D4) that are exposed on the extracellular surface of the cell:
Function
CD4 is a co-receptor of the T cell receptor (TCR) and assists the latter in communicating with antigen-presenting cells. The TCR complex and CD4 bind to distinct regions of the antigen-presenting MHC class II molecule. The extracellular D1 domain of CD4 binds to the ?2 region of MHC class II. The resulting close proximity between the TCR complex and CD4 allows the tyrosine kinase Lck bound to the cytoplasmic tail of CD4 to phosphorylate tyrosine residues of immunoreceptor tyrosine activation motifs (ITAMs) on the cytoplasmic domains of CD3 to amplify the signal generated by the TCR.
T-cell Surface Glycoprotein CD4 Emerging Drugs Chapters
This segment of the T-cell Surface Glycoprotein CD4 report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
T-cell Surface Glycoprotein CD4 Emerging Drugs
Further product details are provided in the report……..
T-cell Surface Glycoprotein CD4: Therapeutic Assessment
This segment of the report provides insights about the different T-cell Surface Glycoprotein CD4 drugs segregated based on following parameters that define the scope of the report, such as:
Phases
DelveInsight’s report covers around 15+ products under different phases of clinical development like
T-cell Surface Glycoprotein CD4: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses T-cell Surface Glycoprotein CD4 therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging T-cell Surface Glycoprotein CD4 drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “T-cell Surface Glycoprotein CD4- Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in T-cell Surface Glycoprotein CD4 pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
T-cell Surface Glycoprotein CD4: Overview
In molecular biology, CD4 (cluster of differentiation 4) is a glycoprotein found on the surface of immune cells such as T helper cells, monocytes, macrophages, and dendritic cells. It was discovered in the late 1970s and was originally known as leu-3 and T4 (after the OKT4 monoclonal antibody that reacted with it) before being named CD4 in 1984. In humans, the CD4 protein is encoded by the CD4 gene. CD4+ T helper cells are white blood cells that are an essential part of the human immune system. They are often referred to as CD4 cells, T-helper cells or T4 cells. They are called helper cells because one of their main roles is to send signals to other types of immune cells, including CD8 killer cells, which then destroy the infectious particle. If CD4 cells become depleted, for example in untreated HIV infection, or following immune suppression prior to a transplant, the body is left vulnerable to a wide range of infections that it would otherwise have been able to fight.
Structure of T-cell Surface Glycoprotein CD4
Like many cell surface receptors/markers, CD4 is a member of the immunoglobulin superfamily. It has four immunoglobulin domains (D1 to D4) that are exposed on the extracellular surface of the cell:
- D1 and D3 resemble immunoglobulin variable (IgV) domains.
- D2 and D4 resemble immunoglobulin constant (IgC) domains.
Function
CD4 is a co-receptor of the T cell receptor (TCR) and assists the latter in communicating with antigen-presenting cells. The TCR complex and CD4 bind to distinct regions of the antigen-presenting MHC class II molecule. The extracellular D1 domain of CD4 binds to the ?2 region of MHC class II. The resulting close proximity between the TCR complex and CD4 allows the tyrosine kinase Lck bound to the cytoplasmic tail of CD4 to phosphorylate tyrosine residues of immunoreceptor tyrosine activation motifs (ITAMs) on the cytoplasmic domains of CD3 to amplify the signal generated by the TCR.
T-cell Surface Glycoprotein CD4 Emerging Drugs Chapters
This segment of the T-cell Surface Glycoprotein CD4 report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
T-cell Surface Glycoprotein CD4 Emerging Drugs
- SAR441236: Sanofi
- Myelin oligodendrocyte glycoprotein transduced T cell therapy: ImCyse
Further product details are provided in the report……..
T-cell Surface Glycoprotein CD4: Therapeutic Assessment
This segment of the report provides insights about the different T-cell Surface Glycoprotein CD4 drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in T-cell Surface Glycoprotein CD4
Phases
DelveInsight’s report covers around 15+ products under different phases of clinical development like
- Late-stage products (Phase II and Phase II/III)
- Mid-stage products (Phase II and Phase II/III)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intramuscular
- Intravenous
- Subcutaneous
- Molecule Type
- Monoclonal antibodies
- Cell-Therapies
- Tri-specific Antibodies
- Product Type
T-cell Surface Glycoprotein CD4: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses T-cell Surface Glycoprotein CD4 therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging T-cell Surface Glycoprotein CD4 drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence T-cell Surface Glycoprotein CD4 R&D. The therapies under development are focused on novel approaches to treat/improve T-cell Surface Glycoprotein CD4.
- T-cell Surface Glycoprotein CD4 Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing T-cell Surface Glycoprotein CD4 drugs?
- How many T-cell Surface Glycoprotein CD4 drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of T-cell Surface Glycoprotein CD4?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the T-cell Surface Glycoprotein CD4 therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for T-cell Surface Glycoprotein CD4 and their status?
- What are the key designations that have been granted to the emerging drugs?
- Biotest AB
- Bristol-Myers Squibb
- CEL-SCI Corp
- Evotec
- Immupharma Plc
- TaiMed Biologics
- United Biomedical
- CEL-1000
- Forigerimod acetate
- Ibalizumab
- M-48U1
- MAX-16H5
- SAR-441236
- TMB-360
- TMB-365
- Tregalizumab
Introduction
Executive Summary
T-cell Surface Glycoprotein CD4: Overview
SYK Receptor - Overview
Structure and Signaling of the SYK Receptor
Regulation of Synthesis and Release of SYK
SYK Metabolism
SYK Receptor Antagonists
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
T-cell Surface Glycoprotein CD4 – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
T-cell Surface Glycoprotein CD4 companies’ collaborations, Licensing, Acquisition -Deal Value Trends
T-cell Surface Glycoprotein CD4 Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Early Stage Products (Phase I)
Comparative Analysis
SAR 441236: Sanofi
Product Description
Research and Development
Product Development Activities
Pre-clinical and Discovery Stage Products
Comparative Analysis
Ibalizumab: TaiMed Biologics
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
T-cell Surface Glycoprotein CD4 Key Companies
T-cell Surface Glycoprotein CD4 Key Products
T-cell Surface Glycoprotein CD4- Unmet Needs
T-cell Surface Glycoprotein CD4- Market Drivers and Barriers
T-cell Surface Glycoprotein CD4- Future Perspectives and Conclusion
T-cell Surface Glycoprotein CD4 Analyst Views
T-cell Surface Glycoprotein CD4 Key Companies
Appendix
Executive Summary
T-cell Surface Glycoprotein CD4: Overview
SYK Receptor - Overview
Structure and Signaling of the SYK Receptor
Regulation of Synthesis and Release of SYK
SYK Metabolism
SYK Receptor Antagonists
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
T-cell Surface Glycoprotein CD4 – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
T-cell Surface Glycoprotein CD4 companies’ collaborations, Licensing, Acquisition -Deal Value Trends
T-cell Surface Glycoprotein CD4 Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Early Stage Products (Phase I)
Comparative Analysis
SAR 441236: Sanofi
Product Description
Research and Development
Product Development Activities
Pre-clinical and Discovery Stage Products
Comparative Analysis
Ibalizumab: TaiMed Biologics
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
T-cell Surface Glycoprotein CD4 Key Companies
T-cell Surface Glycoprotein CD4 Key Products
T-cell Surface Glycoprotein CD4- Unmet Needs
T-cell Surface Glycoprotein CD4- Market Drivers and Barriers
T-cell Surface Glycoprotein CD4- Future Perspectives and Conclusion
T-cell Surface Glycoprotein CD4 Analyst Views
T-cell Surface Glycoprotein CD4 Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for T-cell Surface Glycoprotein CD4
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for T-cell Surface Glycoprotein CD4
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for T-cell Surface Glycoprotein CD4
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for T-cell Surface Glycoprotein CD4
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products